
Danish biotechnology firm Orphazyme, which develops medication for rare diseases, forecasts an operating deficit at DKK 100m-150m (USD 16.2m-24.2m) in 2021, which is significantly lower than the realized deficit for 2020 at DKK 608m, according to the firm's 2020 annual report.
"We expect 2021 to be a transformational year for Orphazyme with the anticipated approval and launch of arimoclomol in NPC (Niemann-Pick type C, -ed.) and two key readouts from our late-stage clinical trials in IBM (inclusion body myositis, -ed.) and ALS (amyotrophic lateral sclerosis, -ed.)," the firm writes in the report.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app